About this Journal Submit a Manuscript Table of Contents
Gastroenterology Research and Practice
Volume 2012 (2012), Article ID 674324, 5 pages
http://dx.doi.org/10.1155/2012/674324
Clinical Study

Comparison between Single-Dose Esomeprazole- and Pantoprazole-Based Triple Therapy on the Effectiveness for Helicobacter pylori Eradication in Taiwanese Population

1Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
2Department of Internal Medicine, Pingtung Hospital, Department of Health, Pingtung, Taiwan
3Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
4Department of Medicine, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
5Department of Gynecology and Obstetrics, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan
6Division of Gastroenterology, Department of Internal Medicine, Buddhist Tzu Chi Hospital and Tzu Chi University, Hualien, Taiwan
7Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan

Received 14 March 2012; Accepted 3 May 2012

Academic Editor: Ping-I Hsu

Copyright © 2012 Hsiang-Yao Shih et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. D. Chey and B. C. Y. Wong, “American College of Gastroenterology guideline on the management of Helicobacter pylori infection,” American Journal of Gastroenterology, vol. 102, no. 8, pp. 1808–1825, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Malfertheiner, F. Megraud, C. O'Morain et al., “Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report,” Gut, vol. 56, no. 6, pp. 772–781, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. J. P. Gisbert, S. Khorrami, X. Calvet, R. Gabriel, F. Carballo, and J. M. Pajares, “Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists-their efficacy with antibiotics in Helicobacter pylori eradication,” Alimentary Pharmacology and Therapeutics, vol. 18, no. 8, pp. 757–766, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. C. M. Spencer and D. Faulds, “Esomeprazole,” Drugs, vol. 60, no. 2, pp. 321–329, 2000. View at Scopus
  5. T. Furuta, N. Shirai, M. Sugimoto, A. Nakamura, A. Hishida, and T. Ishizaki, “Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.,” Drug Metabolism and Pharmacokinetics, vol. 20, no. 3, pp. 153–167, 2005. View at Scopus
  6. R. C. Baselt, Disposition of Toxic Drugs and Chemicals in Man, Biomedical Publications, Seal Beach, Calif, USA, 8th edition, 2011.
  7. I. C. Wu, D. C. Wu, P. I. Hsu et al., “Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection,” Helicobacter, vol. 12, no. 6, pp. 633–637, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. P. I. Hsu, K. H. Lai, C. K. Lin et al., “A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication,” American Journal of Gastroenterology, vol. 100, no. 11, pp. 2387–2392, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. P. I. Hsu, K. H. Lai, C. J. Wu et al., “High-dose versus low-dose esomeprazole-based triple therapy for Helicobacter pylori infection,” European Journal of Clinical Investigation, vol. 37, no. 9, pp. 724–730, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Midolo and B. J. Marshall, “Accurate diagnosis of Helicobacter pylori: urease tests,” Gastroenterology Clinics of North America, vol. 29, no. 4, pp. 871–878, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. C. H. Kuo, H. M. Hu, F. C. Kuo et al., “Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial,” Journal of Antimicrobial Chemotherapy, vol. 63, no. 5, pp. 1017–1024, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. D. M. M. Queiroz, R. Dani, L. D. Silva et al., “Factors associated with treatment failure of Helicobacter pylori infection in a developing country,” Journal of Clinical Gastroenterology, vol. 35, no. 4, pp. 315–320, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Yasuda, Y. Horai, Y. Tomono et al., “Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status,” Clinical Pharmacology and Therapeutics, vol. 58, no. 2, pp. 143–154, 1995. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Becquemont, I. Ragueneau, M. A. Le Bot, C. Riche, C. Funck-Brentano, and P. Jaillon, “Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans,” Clinical Pharmacology and Therapeutics, vol. 61, no. 6, pp. 619–627, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. D. R. Sohn, J. T. Kwon, H. K. Kim, and T. Ishizaki, “Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status,” Clinical Pharmacology and Therapeutics, vol. 61, no. 5, pp. 574–582, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Andersson, M. Hassan-Alin, G. Hasselgren, K. Röhss, and L. Weidolf, “Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole,” Clinical Pharmacokinetics, vol. 40, no. 6, pp. 411–426, 2001. View at Scopus
  17. N. Vakil and F. Megraud, “Eradication Therapy for Helicobacter pylori,” Gastroenterology, vol. 133, no. 3, pp. 985–1001, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. Q. Gu, H. H. X. Xia, J. D. Wang et al., “Update on clarithromycin resistance in Helicobacter pylori in Hong Kong and its effect on clarithromycin-based triple therapy,” Digestion, vol. 73, no. 2-3, pp. 101–106, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. A. H. Huang, B. S. Sheu, H. B. Yang, C. C. Huang, J. J. Wu, and X. Z. Lin, “Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy,” Journal of the Formosan Medical Association, vol. 99, no. 9, pp. 704–709, 2000. View at Scopus
  20. V. F. Roche, “The chemically elegant proton pump inhibitors,” American Journal of Pharmaceutical Education, vol. 70, no. 5, article no. 101, 2006. View at Scopus
  21. J. Kirchheiner, S. Glatt, U. Fuhr et al., “Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH,” European Journal of Clinical Pharmacology, vol. 65, no. 1, pp. 19–31, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Perri, M. R. Villani, V. Festa, M. Quitadamo, and A. Andriulli, “Predictors of failure of Helicobacter pylori eradication with the standard “Maastricht triple therapy”,” Alimentary Pharmacology and Therapeutics, vol. 15, no. 7, pp. 1023–1029, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. J. M. Baena, C. López, A. Hidalgo et al., “Relation between alcohol consumption and the success of Helicobacter pylori eradication therapy using omeprazole, clarithromycin and amoxicillin for 1 week,” European Journal of Gastroenterology and Hepatology, vol. 14, no. 3, pp. 291–296, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. J. M. Kang, N. Kim, D. H. Lee et al., “Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage,” Journal of Gastroenterology and Hepatology, vol. 23, no. 8, pp. 1287–1291, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. V. P. Tan, B. P. Yan, R. H. Hunt, and B. C. Y. Wong, “Proton pump inhibitor and clopidogrel interaction: the case for watchful waiting,” Journal of Gastroenterology and Hepatology, vol. 25, no. 8, pp. 1342–1347, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. P. W. Y. Lim, K. L. Goh, and B. C. Y. Wong, “CYP2C19 genotype and the PPIs - Focus on rabeprazole,” Journal of Gastroenterology and Hepatology, vol. 20, no. 3, supplement, pp. S22–S28, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. P. I. Hsu, K. Lai, and C. Liu, “Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis,” Gastroenterology, vol. 140, no. 3, pp. 791–798, 2011. View at Publisher · View at Google Scholar · View at Scopus